Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Creteil – page 4

644 clinical trials in Creteil, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Creteil at a glance
644
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

644 trials in Creteil

Open in trial search

Glomerulonephritis membranoproliferative+1

Recruiting

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Age-related macular degeneration

Recruiting

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Hormone-dependent prostate cancer

Recruiting

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide

Plasma cell myeloma refractory

Recruiting

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Dry age-related macular degeneration

Recruiting

FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Colorectal cancer stage III

Recruiting

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Nephropathy

Recruiting

A study to evaluate the efficacy and safety of obinutuzumab compared to prednisolone in adults with newly onset minimal change disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Medizinische Universitaet Innsbruck

Progressive supranuclear palsy

Recruiting

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Creteil

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on TTR amyloidosis and heart disease treatments, evaluating novel therapeutic approaches for cardiac conditions. Research includes assessment of innovative medications for chronic kidney disease with hypertension.

  • TTR Amyloidosis Cardiomyopathy
  • Chronic Kidney Disease
  • Hypertension Management
02 Neurological Disorders

Comprehensive research into various neurological conditions, including innovative studies on Huntington's disease biomarkers and treatment approaches for essential tremor and Parkinson's disease.

  • Huntington's Disease Progression
  • Essential Tremor Treatment
  • Parkinson's Disease Management
03 Oncology & Hematology

Advanced clinical trials in blood cancers and solid tumors, including studies of multiple myeloma treatments and novel approaches for non-small cell lung cancer and mesothelioma.

  • Multiple Myeloma Therapies
  • Acute Myeloid Leukemia
  • Lung Cancer Treatment
04 Autoimmune Conditions

Innovative treatments for inflammatory and autoimmune disorders, investigating new therapies for Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis Management
  • Microbiota Transplantation Studies
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.